Fort Myers-based NeoGenomics Inc. is among 77 Florida firms that have been awarded more than $26 million in federal tax credits or grants under a Qualifying Therapeutic Discovery Project program.
NeoGenomics, which specializes in genetic testing for cancer, received two grants, one was for $244,479.24, and the other was for $130,000.
The discovery program is designed to encourage research and development of products that promise to significantly advance health care in the country. The program was created as part of the Patient Protection and Affordable Care Act of 2010.
The maximum award per application was $244,479.25.
To qualify, projects must show the potential to produce new cost-saving therapies, create U.S. jobs, increase the country’s competitiveness, or significantly advance the goal of curing cancer within the next 30 years.